VRSN
58
2
AAPL
58
-3
MRK
64
6
CMCSA
50
4
MAS
50
-4
UNP
48
10
MMC
70
2
AEE
37
4
SYK
60
-10
NFLX
65
-4
HD
55
-2
LUV
63
-2
DHR
45
-5
EXPD
59
5
NDAQ
46
4
MMM
30
4
PYPL
37
4
KHC
29
2
VNO
54
-2
AA
34
3
VRSN
58
2
AAPL
58
-3
MRK
64
6
CMCSA
50
4
MAS
50
-4
UNP
48
10
MMC
70
2
AEE
37
4
SYK
60
-10
NFLX
65
-4
HD
55
-2
LUV
63
-2
DHR
45
-5
EXPD
59
5
NDAQ
46
4
MMM
30
4
PYPL
37
4
KHC
29
2
VNO
54
-2
AA
34
3
Financhill
Back

MediPharm Labs 10K Form

Sell
37

MEDIF
MediPharm Labs

Last Price:
0.05
Seasonality Move:
-13.55%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive MEDIF News And Ratings

See the #1 stock for the next 7 days that we like better than MEDIF

MEDIF Financial Statistics

Sales & Book Value

Annual Sales: $24.49M
Cash Flow: $-1.15M
Price / Cash Flow: 0
Annual Sales: $0.09
Price / Book: 0.62

Profitability

EPS (TTM): -0.02960
Net Income (TTM): $-10.09M
Gross Margin: $4.34M
Return on Equity: -25.01%
Return on Assets: -20.6%

MediPharm Labs Earnings Forecast

Key MediPharm Labs Financial Ratios

  • The Gross Profit Margin over the past 6 years for MEDIF is 17.71%.
  • The Selling, General & Administrative Expenses for MEDIF have been equal to 75.00% of Gross Profit Margin.
  • The Research & Development expenses have been 0.63% of Revenue.
  • The Interest Expense is -2.79% of Operating Income.
  • The Net Earning history of MEDIF is -39.57% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 4 years.

MediPharm Labs Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: OTCM
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: MEDIF
Website: medipharmlabs.com

Debt

Debt-to-Equity Ratio: 0.04
Current Ratio: 3.07
Quick Ratio: 2.06

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

MEDIF Technical Analysis vs Fundamental Analysis

Sell
37
MediPharm Labs (MEDIF) is a Sell

Is MediPharm Labs a Buy or a Sell?

  • MediPharm Labs stock is rated a Sell
    The current MediPharm Labs [MEDIF] share price is $0.06. The Score for MEDIF is 37, which is 26% below its historic median score of 50, and infers higher risk than normal.